Journal article · 2026 · Open access

A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer

邓小虹, Jie Yu, Wenhui Li, Chengkai Zhu, Shijie Hu, Yi Zhang, Guang Liang, Jingnan Zhang

Acta Pharmaceutica Sinica B · Published 1 October 2026 · DOI 10.1016/j.apsb.2026.09.018

Open PDFView at the publisherCite this paper

In brief

“A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer” is a 2026 journal article by 邓小虹 and 7 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
0
References
42
Authors
8

Abstract

Triple-negative breast cancer (TNBC) has a dismal prognosis and few available treatments, posing it a formidable clinical challenge. Here, we identify axis inhibition protein 1 (AXIN1), a key scaffold protein in the Wingless/Int-1 (Wnt) signaling destruction complex, as the direct molecular target of phillygenin. Using integrated approaches including proteomics, bio-layer interferometry, Cellular Thermal Shift Assay (CETSA), and Drug Affinity Responsive Target Stability (DARTS) assays, we demonstrate that phillygenin specifically binds to AXIN1 at Glycine 766 within its Dishevelled (Dvl)-interacting domain (residues 732–862). This binding stabilizes AXIN1 and potently blocks its interaction with Dvl, preventing Dvl-mediated recruitment of AXIN1 to the cell membrane. Consequently, phillygenin maintains the integrity of the β -catenin destruction complex, promotes β -catenin degradation, and suppresses aberrant Wnt/ β -catenin pathway activation in TNBC cells. In vitro , phillygenin dose-dependently inhibits TNBC cell proliferation, migration, and induces apoptosis, effects dependent on AXIN1 expression. In vivo , phillygenin administration significantly suppresses tumor growth and metastasis in both orthotopic 4T1 and patient-derived xenograft (PDX) TNBC models, with efficacy abolished upon AXIN1 knockout. Importantly, phillygenin exhibits minimal cytotoxicity in normal cells. Our findings unveil phillygenin as a first-in-class inhibitor specifically targeting the AXIN1–Dvl interaction, providing a novel and potent therapeutic strategy for TNBC by selectively inhibiting oncogenic Wnt signaling.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

邓小虹, Yu, J., Li, W., Zhu, C., Hu, S., Zhang, Y., Liang, G., & Zhang, J. (2026). A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.018

MLA 9

邓小虹, et al. “A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer.” Acta Pharmaceutica Sinica B, 2026. https://doi.org/10.1016/j.apsb.2026.09.018.

Chicago

邓小虹, Jie Yu, Wenhui Li, Chengkai Zhu, Shijie Hu, Yi Zhang, Guang Liang, and Jingnan Zhang. 2026. “A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer.” Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.018.

Harvard

邓小虹 et al. (2026) ‘A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer’, Acta Pharmaceutica Sinica B. doi:10.1016/j.apsb.2026.09.018.

IEEE

邓小虹 et al., “A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer,” Acta Pharmaceutica Sinica B, 2026, doi: 10.1016/j.apsb.2026.09.018.

BibTeX

@article{2026novel,
  title     = {{A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer}},
  author    = {邓小虹 and Yu, Jie and Li, Wenhui and Zhu, Chengkai and Hu, Shijie and Zhang, Yi and Liang, Guang and Zhang, Jingnan},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2026},
  doi       = {10.1016/j.apsb.2026.09.018},
  url       = {https://doi.org/10.1016/j.apsb.2026.09.018}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • phillygenin
  • triple-negative breast cancer
  • AXIN1
  • Dishevelled
  • β-catenin destruction complex
  • Wnt/β-catenin signaling
  • protein-protein interaction inhibition
  • anticancer natural products

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

邓小虹, Yu, J., Li, W., Zhu, C., Hu, S., Zhang, Y., Liang, G., & Zhang, J. (2026). A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.018

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the PDF from this page.

Who wrote this paper?

邓小虹, Jie Yu, Wenhui Li, Chengkai Zhu, Shijie Hu, Yi Zhang, Guang Liang, Jingnan Zhang.

What is the DOI of this paper?

10.1016/j.apsb.2026.09.018, permanently at https://doi.org/10.1016/j.apsb.2026.09.018. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.